These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 14522889)

  • 21. The T1799A BRAF mutation is present in iris melanoma.
    Henriquez F; Janssen C; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
    Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
    Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
    Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
    Deichmann M; Thome M; Benner A; Näher H
    Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF mutations are detectable in conjunctival but not uveal melanomas.
    Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
    Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
    Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
    Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
    Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of BRAF mutation in primary uveal melanoma.
    Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
    Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
    Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
    Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS
    Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
    Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
    Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses).
    Panagopoulos I; Mertens F; Isaksson M; Mandahl N
    Cancer Genet Cytogenet; 2005 Jan; 156(1):74-6. PubMed ID: 15588860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.